Review: Biologics Help Maintain Intestinal Mucosa Health in Crohn’s, Ulcerative Colitis Patients

Review: Biologics Help Maintain Intestinal Mucosa Health in Crohn’s, Ulcerative Colitis Patients
Specific biologic treatments don't only relieve symptoms but can also maintain intestinal health in patients with inflammatory bowel disease (IBD), according to a review that analyzed medicines approved by the U.S. Food and Drug Administration (FDA) to treat IBD. The study “Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials,” appeared in the journal Alimentary Pharmacology & Therapeutics. Doctors have used therapeutics mostly as a means to relieve patients of IBD-related symptoms. Recently, however, this strategy is shifting and IBD treatments increasingly target intestinal mucosal healing. This is because in many cases, the mucosa — or inner layer of the gastrointestinal tract — often remains ulcerated, with patients ultimately requiring surgery. While several drugs are approved IBD therapeutics, researchers weren't sure which were best at healing the intestinal mucosa. Now, a team of researchers has performed a systematic review and analysis of randomized controlled trials investigating mucosal healing with different treatments. Specifically, the study aimed to "examine the efficacy of each therapeutic class in inducing and maintaining mucosal healing in moderate-to-severe Crohn’s disease and ulcerative colitis (UC), and to perform network meta-analysis utilizing direct and indirect evidence from clinical trials to derive comparative efficacy of various therapies in achieving mucosal healing.” The analysis included only FDA-approved therap
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *